Cochrane · systematic review · CD009182
Nitazoxanide for chronic hepatitis C
Nikolova, K, Gluud, C, Grevstad, B, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
21
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 14 · 40%Very low 13 · 37.1%Low 8 · 22.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Nitazoxanide for chronic hepatitis C
Population: people with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias |
Chronic hepatitis C‐related mortality | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias |
Morbidity | no estimate extracted | 0 participants | Ungraded |
Adverse events | RR 1.1 [0.71, 1.71] | 4 studies · 383 participants | Very low Downgraded: risk of bias |
Failure of sustained virological response | RR 0.85 [0.75, 0.97] | 7 studies · 498 participants | Low Downgraded: risk of bias |
Failure of virological end‐of‐treatment response | RR 0.81 [0.69, 0.96] | 7 studies · 498 participants | Low Downgraded: risk of bias |
Participants without improvement in ALT and/or AST serum levels | RR 1.09 [0.84, 1.42] | 3 studies · 271 participants | Very low Downgraded: risk of bias |
Nitazoxanide for chronic hepatitis C
Population: people with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 0 participants | Ungraded |
Chronic hepatitis C‐related mortality | no estimate extracted | 0 participants | Ungraded |
Morbidity | no estimate extracted | 0 participants | Ungraded |
Adverse events | RR 1.83 [0.8, 4.19] | 1 study · 50 participants | Very low Downgraded: risk of bias |
Failure of sustained virological response | RR 0.84 [0.7, 1.01] | 1 study · 50 participants | Low Downgraded: risk of bias |
Failure of virological end‐of‐treatment response | RR 0.73 [0.56, 0.93] | 1 study · 50 participants | Low Downgraded: risk of bias |
Participants without improvement in ALT and/or AST serum levels | RR 0.9 [0.66, 1.23] | 1 study · 50 participants | Low Downgraded: risk of bias |
Nitazoxanide for chronic hepatitis C
Population: people with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 0 participants | Ungraded |
Chronic hepatitis C‐related mortality | no estimate extracted | 0 participants | Ungraded |
Morbidity | no estimate extracted | 0 participants | Ungraded |
Adverse events | RR 0.78 [0.33, 1.84] | 1 study · 112 participants | Very low Downgraded: risk of bias |
Failure of sustained virological response | RR 0.85 [0.72, 1] | 3 studies · 217 participants | Low Downgraded: risk of bias |
Failure of virological end‐of‐treatment response | RR 0.73 [0.6, 0.89] | 3 studies · 217 participants | Low Downgraded: risk of bias |
Participants without improvement in ALT and/or AST serum levels | no estimate extracted | 0 participants | Ungraded |
Nitazoxanide for chronic hepatitis C
Population: people with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias |
Chronic hepatitis C‐related mortality | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias |
Morbidity | no estimate extracted | 0 participants | Ungraded |
Adverse events | RR 1 [0.51, 1.96] | 2 studies · 181 participants | Very low Downgraded: risk of bias |
Failure of sustained virological response | RR 0.88 [0.65, 1.19] | 2 studies · 181 participants | Low Downgraded: risk of bias |
Failure of virological end‐of‐treatment response | RR 1.16 [0.78, 1.73] | 2 studies · 181 participants | Very low Downgraded: risk of bias |
Participants without improvement in ALT and/or AST serum levels | RR 1.24 [0.85, 1.8] | 2 studies · 181 participants | Very low Downgraded: risk of bias |
Nitazoxanide for chronic hepatitis C
Population: people with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 0 participants | Ungraded |
Chronic hepatitis C‐related mortality | no estimate extracted | 0 participants | Ungraded |
Morbidity | no estimate extracted | 0 participants | Ungraded |
Adverse events | no estimate extracted | 0 participants | Ungraded |
Failure of sustained virological response | RR 0.79 [0.38, 1.62] | 1 study · 50 participants | Very low Downgraded: risk of bias |
Failure of virological end‐of‐treatment response | RR 0.54 [0.22, 1.36] | 1 study · 50 participants | Very low Downgraded: risk of bias |
Participants without improvement in ALT and/or AST serum levels | no estimate extracted | 0 participants | Ungraded |